CLINICAL LABORATORY INDICATORS OF PREGNANT WITH ANTIPHOSPHOLIPID SYNDROME IN COMPLEX THERAPY WITH USING INTRAVENOUS IMMUNOGLOBULIN

Abstract

Objective: to study clinical and laboratory indicators of influence of intravenous immunoglobulin (IV-Ig) in complex therapy of pregnant women with syndrome of fetal loss syndrome. Materials and methods. Study included 63 pregnant women with fetal loss syndrome caused by APS. They were divided into 2 groups depending on therapy. The patients in group I (n=35) - received anticoagulant, antiplatelet and antioxidant therapy. The patients in group II (n=28), in addition to conventional treatment received IV-Ig. Laboratory studies included determination of antiphospholipid antibodies lupus anticoagulant, concentration of anticardiolipin antibody, antibodies to β2-glycoprotein, annexin V, phrotrombin. Diagnosis of blood thrombophilia included determination of aggregate platelet function, molecular markers of thrombophilia - TAT (fragments of thrombin-antithrombin), D-dimer (fibrin polymerization). Evaluated the content of the main subpopulations of immune cells in the peripheral blood, the absolute and relative abundance of cells with the phenotype CD3 + (T-lymphocytes). Results. The results of laboratory and clinical studies of the IV-Ig in the treatment of fetal loss syndrome, which is caused by antiphospholipid syndrome. In the group of pregnant women who received therapy IV-Ig, marked decrease in levels antiphospholipid antibodies, markers of thrombophilia, reducing the frequency of pregnancy complications and improve perinatal indicators. Conclusion. It is noted that immune-modulating effect is probably related to its positive impact on the function of T-regulatory lymphocytes.

Keywords

• antiphospholipid syndrome
• hemostasis system
• fetal loss syndrome
• inravenous immunoglobulin
• immunocompetent lymphocytes